PCSA
Processa Pharmaceuticals, Inc.
Price Chart
Latest Quote
$2.15
+0.03 (+1.42%)
Current Price
| Previous Close | $2.12 |
| Open | $2.17 |
| Day High | $2.32 |
| Day Low | $2.12 |
| Volume | 10,109 |
Stock Information
| Shares Outstanding | 2.77M |
| Cash Equivalents | $1.69M |
| Net Income | $-14.11M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.76M |
| EPS (TTM) | $-4.07 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.14M |
| Income | $-14.11M |
| Book/sh | $0.95 |
| Cash/sh | $0.61 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 0.85 |
| Current Ratio | 0.98 |
Returns & Margins
| ROA | -193.89% |
| ROE | -464.99% |
Ownership
| Insider Ownership | 14.40% |
| Institutional Ownership | 10.24% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.55 |
| P/B | 2.19 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.39 |
| SMA50 | $2.64 |
| SMA200 | $4.28 |
| RSI | 39.82 |
| ATR | 0.3164 |
| Shares Float | 2.66M |
| Short Float | 3.81% |
| Short Ratio | 1.58 |
| Volatility | 0.96 |
| Rel Volume | 0.24 |
Performance History
| Week | -4.15% |
| Month | -20.31% |
| Quarter | -10.34% |
| 6 Months | -68.86% |
| YTD | -29.01% |
| Year | -65.62% |
| 3 Years | -99.39% |
| 5 Years | -99.94% |
| 10 Years | -99.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $2.08 | 15,801 |
| 2026-06-18 | $2.12 | 18,300 |
| 2026-06-17 | $2.15 | 73,800 |
| 2026-06-16 | $2.09 | 62,800 |
| 2026-06-15 | $2.21 | 29,700 |
| 2026-06-12 | $2.17 | 52,400 |
| 2026-06-11 | $2.37 | 175,700 |
| 2026-06-10 | $1.98 | 174,900 |
| 2026-06-09 | $2.04 | 108,600 |
| 2026-06-08 | $2.42 | 16,800 |
| 2026-06-05 | $2.52 | 32,100 |
| 2026-06-04 | $2.75 | 40,100 |
| 2026-06-03 | $2.80 | 25,100 |
| 2026-06-02 | $2.92 | 154,800 |
| 2026-06-01 | $2.53 | 72,400 |
| 2026-05-29 | $2.56 | 22,700 |
| 2026-05-28 | $2.64 | 110,600 |
| 2026-05-27 | $2.39 | 36,400 |
| 2026-05-26 | $2.50 | 45,400 |
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
đ° Latest News
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
MT Newswires âĸ 2025-12-18T14:23:13ZTop Midday Gainers
MT Newswires âĸ 2025-12-17T18:37:48ZWill Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Simply Wall St. âĸ 2025-12-17T10:43:26Z
Insider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This Week
Simply Wall St. âĸ 2025-08-06T11:20:01Z
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
Insider Monkey âĸ 2025-07-11T23:26:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $13,988,505 | $12,051,206 | $11,457,061 | $20,257,288 |
| Other Income Expense | $315,180 | - | - | $-7,268,143 |
| Other Non Operating Income Expenses | $20,000 | - | - | - |
| Net Non Operating Interest Income Expense | $109,491 | $201,088 | $335,541 | $101,202 |
| Operating Expense | $13,988,505 | $12,051,206 | $11,457,061 | $20,257,288 |
| General And Administrative Expense | $6,178,168 | $4,782,060 | $5,657,543 | $8,763,058 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Net Interest Income | $109,491 | $201,088 | $335,541 | $101,202 |
| Interest Income | $109,491 | $201,088 | $335,541 | $101,202 |
| Normalized Income | $-13,859,014 | $-11,850,118 | $-11,121,520 | $-20,156,086 |
| Net Income From Continuing And Discontinued Operation | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Total Operating Income As Reported | $-13,988,505 | $-12,051,206 | $-11,457,061 | $-27,525,431 |
| Net Income Common Stockholders | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Net Income | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Net Income Including Noncontrolling Interests | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Net Income Continuous Operations | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Pretax Income | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Interest Income Non Operating | $109,491 | $201,088 | $335,541 | $101,202 |
| Operating Income | $-13,988,505 | $-12,051,206 | $-11,457,061 | $-20,257,288 |
| Special Income Charges | - | - | $0 | $-7,268,143 |
| Per Share | ||||
| Diluted EPS | $-10.36 | $-96.78 | $-212.00 | $-851.25 |
| Basic EPS | $-10.36 | $-96.78 | $-212.00 | $-851.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-14,282,481 | $-12,050,424 | $-11,456,839 | $-12,200,650 |
| Total Unusual Items | $295,180 | - | $0 | $-7,268,143 |
| Total Unusual Items Excluding Goodwill | $295,180 | - | $0 | $-7,268,143 |
| Reconciled Depreciation | $1,204 | $782 | $222 | $788,495 |
| EBITDA (Bullshit earnings) | $-13,987,301 | $-12,050,424 | $-11,456,839 | $-19,468,793 |
| EBIT | $-13,988,505 | $-12,051,206 | $-11,457,061 | $-20,257,288 |
| Diluted Average Shares | $1,309,271 | $122,438 | $52,462 | $32,219 |
| Basic Average Shares | $1,309,271 | $122,438 | $52,462 | $32,219 |
| Diluted NI Availto Com Stockholders | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Tax Provision | $0 | - | $0 | $0 |
| Gain On Sale Of Security | $295,180 | - | - | - |
| Research And Development | $7,810,337 | $7,269,146 | $5,799,518 | $11,494,230 |
| Selling General And Administration | $6,178,168 | $4,782,060 | $5,657,543 | $8,763,058 |
| Other Gand A | $6,178,168 | $4,782,060 | $5,657,543 | $8,763,058 |
| Impairment Of Capital Assets | - | - | $0 | $7,268,143 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,577,314 | $1,696,171 | $4,989,159 | $7,470,741 |
| Total Assets | $7,813,567 | $3,229,289 | $5,786,643 | $8,619,851 |
| Total Non Current Assets | $2,142,693 | $1,350,135 | $154,146 | $233,122 |
| Other Non Current Assets | $1,145,180 | $5,535 | $5,535 | $5,535 |
| Non Current Prepaid Assets | $993,701 | $1,274,442 | $0 | - |
| Current Assets | $5,670,874 | $1,879,154 | $5,632,497 | $8,386,729 |
| Other Current Assets | $133,919 | $687,829 | $926,300 | $1,883,134 |
| Cash Cash Equivalents And Short Term Investments | $5,536,955 | $1,191,325 | $4,706,197 | $6,503,595 |
| Cash And Cash Equivalents | $5,536,955 | $1,191,325 | $4,706,197 | $6,503,595 |
| Goodwill And Other Intangible Assets | - | - | $0 | $0 |
| Prepaid Assets | - | - | - | $1,883,134 |
| Receivables | - | - | - | $0 |
| Taxes Receivable | - | - | - | $0 |
| Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $0 | $73,507 | $150,554 | $229,450 |
| Long Term Debt And Capital Lease Obligation | $0 | $487 | $66,905 | $150,554 |
| Current Debt And Capital Lease Obligation | - | $73,020 | $83,649 | $78,896 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,236,253 | $1,533,118 | $797,484 | $1,149,110 |
| Total Non Current Liabilities Net Minority Interest | $0 | $487 | $66,905 | $150,554 |
| Current Liabilities | $2,236,253 | $1,532,631 | $730,579 | $998,556 |
| Payables And Accrued Expenses | $2,236,253 | $1,459,611 | $646,930 | $919,660 |
| Payables | $1,056,796 | $880,880 | $500,656 | $516,599 |
| Accounts Payable | $1,056,796 | $880,880 | $311,617 | $327,548 |
| Other Payable | - | - | $189,000 | $189,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Non Current Deferred Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $5,577,314 | $1,696,171 | $4,989,159 | $7,470,741 |
| Total Equity Gross Minority Interest | $5,577,314 | $1,696,171 | $4,989,159 | $7,470,741 |
| Stockholders Equity | $5,577,314 | $1,696,171 | $4,989,159 | $7,470,741 |
| Retained Earnings | $-100,783,033 | $-87,219,199 | $-75,369,081 | $-64,247,561 |
| Other | ||||
| Treasury Shares Number | $200 | $200 | $200 | $200 |
| Ordinary Shares Number | $2,571,914 | $148,105 | $51,440 | $32,070 |
| Share Issued | $2,572,114 | $148,305 | $51,640 | $32,270 |
| Tangible Book Value | $5,577,314 | $1,696,171 | $4,989,159 | $7,470,741 |
| Invested Capital | $5,577,314 | $1,696,171 | $4,989,159 | $7,470,741 |
| Working Capital | $3,434,621 | $346,523 | $4,901,918 | $7,388,173 |
| Capital Lease Obligations | $0 | $73,507 | $150,554 | $229,450 |
| Total Capitalization | $5,577,314 | $1,696,171 | $4,989,159 | $7,470,741 |
| Treasury Stock | $300,000 | $300,000 | $300,000 | $300,000 |
| Additional Paid In Capital | $106,660,090 | $89,215,355 | $80,658,111 | $72,018,222 |
| Capital Stock | $257 | $15 | $129 | $80 |
| Common Stock | $257 | $15 | $129 | $80 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $0 | $487 | $66,905 | $150,554 |
| Current Capital Lease Obligation | $0 | $73,020 | $83,649 | $78,896 |
| Current Accrued Expenses | $1,179,457 | $578,731 | $146,274 | $403,061 |
| Net PPE | $3,812 | $75,693 | $148,611 | $227,587 |
| Gross PPE | $3,812 | $75,693 | $148,611 | $227,587 |
| Other Properties | $3,812 | $75,693 | $148,611 | $227,587 |
| Dueto Related Parties Current | - | $0 | $39 | $51 |
| Accumulated Depreciation | - | - | - | - |
| Machinery Furniture Equipment | - | - | - | - |
| Duefrom Related Parties Current | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,235,195 | $-11,248,286 | $-8,066,122 | $-9,605,143 |
| Operating Activities | ||||
| Operating Cash Flow | $-11,385,195 | $-11,245,042 | $-8,063,346 | $-9,605,143 |
| Cash Flow From Continuing Operating Activities | $-11,385,195 | $-11,245,042 | $-8,063,346 | $-9,605,143 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-850,000 | $-3,244 | $-2,776 | - |
| Investing Cash Flow | $-850,000 | $-3,244 | $-2,776 | $0 |
| Cash Flow From Continuing Investing Activities | $-850,000 | $-3,244 | $-2,776 | $0 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-10,404 | $-15,902 | $0 | $-388,843 |
| Issuance Of Capital Stock | $16,597,831 | $7,763,079 | $6,321,470 | $0 |
| Financing Cash Flow | $16,580,825 | $7,733,414 | $6,268,724 | $-388,843 |
| Cash Flow From Continuing Financing Activities | $16,580,825 | $7,733,414 | $6,268,724 | $-388,843 |
| Net Common Stock Issuance | $16,587,427 | $7,747,177 | $6,321,470 | $-388,843 |
| Common Stock Issuance | $16,597,831 | $7,763,079 | $6,321,470 | $0 |
| Net Other Financing Charges | - | $-8,561 | $-52,746 | - |
| Other | ||||
| Repayment Of Debt | $-6,602 | $-5,202 | $0 | - |
| Interest Paid Supplemental Data | $5,607 | $1,204 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $5,536,955 | $1,191,325 | $4,706,197 | $6,503,595 |
| Beginning Cash Position | $1,191,325 | $4,706,197 | $6,503,595 | $16,497,581 |
| Changes In Cash | $4,345,630 | $-3,514,872 | $-1,797,398 | $-9,993,986 |
| Common Stock Payments | $-10,404 | $-15,902 | $0 | $-388,843 |
| Net Issuance Payments Of Debt | $-6,602 | $-5,202 | $0 | - |
| Net Long Term Debt Issuance | $-6,602 | $-5,202 | $0 | - |
| Long Term Debt Payments | $-6,602 | $-5,202 | $0 | - |
| Net Intangibles Purchase And Sale | $-850,000 | $0 | - | - |
| Purchase Of Intangibles | $-850,000 | $0 | - | - |
| Net PPE Purchase And Sale | $0 | $-3,244 | $-2,776 | $0 |
| Purchase Of PPE | $0 | $-3,244 | $-2,776 | $0 |
| Change In Working Capital | $1,544,388 | $-112,404 | $605,208 | $543,604 |
| Change In Other Current Liabilities | $-66,905 | $-83,649 | $-78,896 | $-87,937 |
| Change In Payables And Accrued Expense | $776,642 | $1,001,720 | $-272,718 | $352,439 |
| Change In Accrued Expense | $600,726 | $432,457 | $-256,787 | $243,796 |
| Change In Payable | $175,916 | $569,263 | $-15,931 | $108,643 |
| Change In Account Payable | $175,916 | $569,263 | $-15,931 | $108,643 |
| Change In Prepaid Assets | $834,651 | $-1,030,436 | $956,834 | $210,549 |
| Change In Receivables | $0 | $-39 | $-12 | $70,274 |
| Other Non Cash Items | $70,677 | $87,184 | $1,392,405 | $390,131 |
| Stock Based Compensation | $857,550 | $629,514 | $1,060,339 | $8,828,713 |
| Unrealized Gain Loss On Investment Securities | $-295,180 | $0 | - | - |
| Depreciation Amortization Depletion | $1,204 | $782 | $222 | $788,495 |
| Depreciation And Amortization | $1,204 | $782 | $222 | $788,495 |
| Depreciation | $1,204 | $782 | $222 | $0 |
| Net Income From Continuing Operations | $-13,563,834 | $-11,850,118 | $-11,121,520 | $-27,424,229 |
| Change In Other Working Capital | - | - | $-12 | $-1,721 |
| Asset Impairment Charge | - | - | $0 | $7,268,143 |
| Amortization Cash Flow | - | - | $0 | $788,495 |
| Amortization Of Intangibles | - | - | $0 | $788,495 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Change In Interest Payable | - | - | - | - |
Fetched: 2026-06-17